logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Marthe S. Paats

erasmus mc cancer institute
H指数:18
被引数:1,210

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study

确定识别奥希康替尼耐药性的最佳方法；OSIRIS研究中的奥希康替尼一线治疗队列

Lung Cancer
IF4.4
2025-09-280
PRE
J.W.T. van der Wel; S.M. Ernst; M. Jebbink; D. van den Broek; S.K. Badrising; L.C. Steinbusch; G. Ruiter; W.S.M.E. Theelen; B.A.M.H. van Veggel; J. Smit; A.M. Dingemans; M.S. Paats; H.J. Dubbink; S.M.S. Hashemi; T. Radonic; D. Cohen; A.J. van der Wekken; A. ter Elst; W. Timens; L.E. Hendriks; E.J.M. Speel; M.M.J. Disselhorst; A. Welling; F. van der Meer; L.J.W. Bosch; K. Monkhorst; M.C. Boelens; E.F. Smit; A.J. de Langen
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study

司美格鲁肽降低阿来替尼的生物利用度：一项基于交叉药代动力学药物相互作用研究的警告说明

Cancer Communications
IF24.9
2025-05-010
OAAI
Niels Heersche; Daan A. C. Lanser; Esther Oomen-de Hoop; Attila Içli; Peter de Bruijn; Marthe S. Paats; Elisabeth F. C. van Rossum; Stijn L. W. Koolen; Ron H. N. van Schaik; Anne-Marie C. Dingemans; G. D. Marijn Veerman; Ron H. J. Mathijssen
Molecular Tumor Board of the University Medical Center Groningen (UMCGMTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

格罗宁根大学医学中心 (UMCGMTB) 的分子肿瘤委员会: 接受MTB建议的靶向治疗的罕见或复杂突变特征的患者的结果

ESMO OPEN
IF8.3
2024-11-010
OAAI
deJager, V. D.; Plomp, P.; Paats, M. S.; van Helvert, S.; ter Elst, A.; van den Berg, A.; Dubbink, H. J.; van Geffen, W. H.; Zhang, L.; Hendriks, L. E. L.; Hiltermann, T. J. N.; Hiddinga, B. I.; Hijmering-Kappelle, L. B. M.; Jalving, M.; Kluiver, J.; Koopman, B.; van Kruchten, M.; van der Logt, E. M. J.; Piet, B.; van Putten, J.; Reitsma, B. H.; Rutgers, S. R.; de Vries, M.; Stigt, J. A.; Groves, M. R.; Timens, W.; Willems, S. M.; van Kempent, L. C.; Schuuring, E.; van der Wekken, A. J.
Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib

共有的胚系变异对阿来替尼毒性特征和药代动力学的影响

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Heersche, N.; Lanser, D. A. C.; Muntinghe, B.; Ali, M. I. Mohmaed; Ulas, E. B.; Trooster, T. M. A.; de Jonge, E.; Oomen-de Hoop, E.; Paats, M. S.; Bahce, I.; Croes, S.; Hendriks, L. E.; Van der Wekken, A. J.; Dingemans, A-M. C.; Huitema, A. D. R.; Van Schaik, R.; Mathijssen, R. H.; Veerman, M. G. D.
Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance

结合循环肿瘤DNA和肿瘤组织的分子联合分析以识别奥希替尼耐药性

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
van der Wel, T.; Jebbink, M.; Badrising, S.; Steinbusch, L.; Ruiter, G.; Theelen, W. S. M. E.; Veggel, B. V.; Smit, J.; Hashemi, S.; Van Der Wekken, A. J.; Hendriks, L. E.; Paats, M. S.; Ernst, S.; Van Den Broek, D.; Bosch, L. J. W.; Monkhorst, K.; Smit, E. F.; Boelens, M. C.; De langen, A. J.
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
EBIOMEDICINE
IF10.8
2024-04-017
OAAI
Ernst, Sophie M.; Hofman, Maaike M.; van der Horst, Tessa E.; Paats, Marthe S.; Aerts, Joachim G. J. V.; Heijboer, Frank W. J.; Dumoulin, Daphne W.; Cornelissen, Robin; von der Thusen, Jan H.; de Bruijn, Peter; Hoop, Esther Oomen-de; Mathijssen, Ron H. J.; Koolen, Stijn L. W.; Dingemans, Anne -Marie C.
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer

阿法替尼联合西妥昔单抗治疗EGFR外显子20插入阳性非小细胞肺癌的2期临床试验

CANCER
IF5.1
2023-10-312
OAAI
van Veggel, Bianca A. M. H.; van der Wekken, Anthonie J.; Paats, Marthe S.; Hendriks, Lizza E. L.; Hashemi, Sayed M. S.; Daletzakis, Antonios; van den Broek, Daan; Bosch, Linda J. W.; Monkhorst, Kim; Smit, Egbert F.; de Langen, Adrianus J.
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer
INTERNATIONAL JOURNAL OF CANCER
IF4.7
2023-10-156
OA
van Veelen, Ard; Veerman, G. D. Marijn; Verschueren, Marjon V.; Gulikers, Judith L.; Steendam, Christi M. J.; Brouns, Anita J. W. M.; Dursun, Safiye; Paats, Marthe S.; Tjan-Heijnen, Vivianne C. G.; van der Leest, Cor; Dingemans, Anne-Marie C.; Mathijssen, Ron H. J.; van de Garde, Ewoudt M. W.; Souverein, Patrick; Driessen, Johanna H. M.; Hendriks, Lizza E. L.; van Geel, Robin M. J. M.; Croes, Sander
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

曲妥珠单抗-Emtansine和奥希替尼联合治疗靶向EGFR突变阳性NSCLC的HER2旁路耐药

JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2023-04-0115
OA
Jebbink, M.; de Langen, A. J.; Monkhorst, K.; Boelens, M. C.; van den Broek, D.; van der Noort, V.; de Gooijer, C. J.; Mahn, M.; van der Wekken, A. J.; Hendriks, L.; Hashemi, S. M. S.; Paats, M. S.; Dingemans, A. C.; Smit, E. F.
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
FRONTIERS IN ONCOLOGY
IF3.3
2023-03-095
OAAI
Meertens, Marinda; Muntinghe-Wagenaar, M. Benthe; Sikkema, Barend J.; Lopez-Yurda, Marta; Retel, Valesca P.; Paats, Marthe S.; Ter Heine, Rob; Schuuring, Ed; Timens, Wim; Touw, Daan J.; van Boven, Job F. M.; de Langen, Adrianus. J.; Hashemi, Sayed M. S.; Hendriks, Lizza E. L.; Croes, Sander; van den Heuvel, Michel M.; Dingemans, Anne-Marie C.; Mathijssen, Ron H. J.; Smit, Egbert F.; Huitema, Alwin D. R.; Steeghs, Neeltje; van der Wekken, Anthonie J.

研究方向

暂未获取到该数据
A
Anne‐Marie C. Dingemans
H 指数:71论文数:674被引数:2.0万
R
Ron H.J. Mathijssen
H 指数:76论文数:888被引数:2.0万
L
Lizza Hendriks
H 指数:48论文数:432被引数:1.0万
A
Anthonie J. van der Wekken
H 指数:29论文数:192被引数:4,497
E
Egbert F. Smit
H 指数:113论文数:1,213被引数:6.0万
E
Esther Oomen‐de Hoop
H 指数:31论文数:204被引数:3,254
P
Peter de Bruijn
H 指数:38论文数:265被引数:7,220
D
D. Lanser
H 指数:4论文数:22被引数:96
K
Kim Monkhorst
H 指数:41论文数:391被引数:7,471
S
Sayed M.S. Hashemi
H 指数:23论文数:95被引数:2,208